Dr. Sayed M. Husain, M.D.
Nephrology (Kidney) (Nephrology Physician)
- Medicare participating
At a glance
- Years since graduation
- 21
- In the NPI registry since
- 2011
- Medicare patients seen, 2024
- 379
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2011Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Nephrology Physician primary
FL license ME128664 -
Hospitalist Physician
TN license 50101 -
Internal Medicine Physician
TN license 50101
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Adventhealth Orlando Orlando, FL
- Orlando Health Orlando, FL
- Adventhealth Deland Deland, FL
- Adventhealth Fish Memorial Orange City, FL
- Central Florida Lake Monroe Hospital Sanford, FL
Medical groups
- Mid Florida Kidney and Hypertension Care Pl (2 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 379
- Services billed
- 2,661
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | 504 | 80 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 414 | 184 |
| Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | 390 | 69 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 281 | 110 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 175 | 142 |
| Established patient office or other outpatient visit, 20-29 minutes | 165 | 93 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 100 | 24 |
| Remote monitoring of physiologic parameters, initial set-up and patient education on use of equipment | 74 | 69 |
| Dialysis services, 4 or more physician visits per month (20 years or older) | 54 | 20 |
| Established patient office or other outpatient visit, 10-19 minutes | 42 | 39 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 7 companies reported 17 payments worth $528 in total to this clinician.
| Amgen Inc. | $263 |
|---|---|
| Calliditas Therapeutics US Inc. | $145 |
| AstraZeneca Pharmaceuticals LP | $39.71 |
| Akebia Therapeutics Inc | $28.84 |
| Fresenius USA Marketing, Inc. | $24.26 |
| Travere Therapeutics, Inc. | $14.15 |
| Aurinia Pharma U.S., Inc. | $13.83 |
| Food and Beverage | $514 |
|---|---|
| Education | $14.15 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Travere Therapeutics, Inc. Aug 25, 2025 | Education Filspari · Kidney Disease · in-kind | $11.77 |
| Travere Therapeutics, Inc. Aug 5, 2025 | Education Filspari · Kidney Disease · in-kind | $2.38 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $58,442 in research payments for these studies, mostly to the institutions running them.
- A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Aged 18 Years and Older With APOL1-mediated Proteinuric Kidney Disease
Vertex Pharmaceuticals Incorporated - LUPKYNIS Registry Study
Aurinia Pharma U.S., Inc. - Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
Csl Behring · Recruiting · NCT05485961
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.